Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator-mediated extracellular matrix degradation in human osteosarcoma cell line MG63 by interleukin-1 alpha
- PMID: 7502710
- DOI: 10.1002/jbmr.5650100915
Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator-mediated extracellular matrix degradation in human osteosarcoma cell line MG63 by interleukin-1 alpha
Abstract
Plasmin-mediated extracellular proteolysis has been implicated in the degradation of bone in normal and pathological conditions. Normal and malignant osteoblasts can produce both tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA). We have used the osteosarcoma cell line MG63 to address the question of whether the enhanced bone turnover in osteosarcomas is mediated by t-PA or by u-PAA and to study the effect of the cytokine interleukin-1 alpha (IL-1 alpha), known to influence bone degradation, on the plasminogen activator production and extracellular matrix degradation in malignant osteoblastic cells. Furthermore, the effect of IL-1 alpha on the synthesis of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) was analyzed. u-PA production by MG63 was high (approximately 180 ng/10(6) cells/24 h). Also t-PA and PAI-1 production was observed. u-PA production was rapidly increased in MG63 by IL-1 alpha (10 ng/ml), whereas an effect on t-PA production was only found after a prolonged incubation and hardly any effect of IL-1 alpha on PAI-1 production was observed. mRNA analysis revealed similar effects. u-PA receptor (u-PAR) mRNA was detectable in MG63 cells and could be increased by IL-1 alpha after 24 h. In MG63, u-PA-mediated extracellular matrix degradation was detectable, and IL-1 alpha increased the u-PA-mediated matrix degradation (approximately 2-fold). Under control conditions in MG63, only MMP-2, TIMP-1, and TIMP-2 mRNA could be observed. After the addition of IL-1 alpha, a very rapid increase in MMP-1 and MMP-3 mRNA could be observed as well as a moderate increase in TIMP-1 mRNA. The presence of MMP-2 was demonstrated by gelatin zymography. These results show that IL-1 alpha can stimulate u-PA production and can regulate extracellular proteolytic activity mainly via u-PA induction in the MG63 osteosarcoma cell line. Furthermore, IL-1 alpha has a strong stimulating effect on the production of MMP-1 and MMP-3. These findings suggest that u-PA and possibly MMP-1 and MMP-3 play an important role in the process of bone turnover in osteosarcomas.
Similar articles
-
The effect of IL-1alpha on the expression of matrix metalloproteinases, plasminogen activators, and their inhibitors in osteoblastic ROS 17/2.8 cells.Life Sci. 2006 Mar 20;78(17):1975-82. doi: 10.1016/j.lfs.2005.08.036. Epub 2005 Nov 28. Life Sci. 2006. PMID: 16313928
-
In vitro effects of interleukin 1 on the synthesis of metalloproteases, TIMP, plasminogen activators and inhibitors in human articular cartilage.J Rheumatol Suppl. 1991 Feb;27:80-4. J Rheumatol Suppl. 1991. PMID: 1851231
-
Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2799-805. Invest Ophthalmol Vis Sci. 2002. PMID: 12147618
-
The fibrinolytic system in neoplasia.Semin Thromb Hemost. 1996;22(6):459-78. doi: 10.1055/s-2007-999047. Semin Thromb Hemost. 1996. PMID: 9122711 Review.
-
Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis.Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):1104-17. doi: 10.1161/hq0701.093685. Arterioscler Thromb Vasc Biol. 2001. PMID: 11451738 Review.
Cited by
-
Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its development.Oncotarget. 2016 Jul 12;7(28):44790-44802. doi: 10.18632/oncotarget.8316. Oncotarget. 2016. PMID: 27027349 Free PMC article. Review.
-
c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells.Clin Exp Metastasis. 2003;20(5):421-30. doi: 10.1023/a:1025404603315. Clin Exp Metastasis. 2003. PMID: 14524531
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous